hmmm....EBITDA in FY20 & FY21 was ~12m off revenues of 100-105m
FY2022 forecast revenues of 115m (so a ~9% inprovement) but resulting in a reduction in EBITDA ("low single-digit").
Their June strategy presentation indicated (at least for FY21) that EBITDA would be ~10% of revenues and long term (FY24) would improve to 15-20%, but this guidance seems to actually show EBITDA margins reducing.....more spend on R&D and S&M in the short term??
Ann: Gentrack provides updated guidance for FY22, page-11
-
- There are more pages in this discussion • 6 more messages in this thread...
You’re viewing a single post only. To view the entire thread just sign in or Join Now (FREE)
